MARGARET K. YU, M.D.
DISEASE AREA STRONGHOLD LEADER, PROSTATE CANCER
Margaret K. Yu, M.D. is Vice President, Prostate Cancer Disease Area Stronghold (DAS) Leader at Janssen Research & Development, LLC. Her role is to oversee all the responsibilities for both matrix and direct line management of the Prostate Cancer DAS.
Margaret joined Janssen as a Medical Director, was quickly promoted to Clinical Leader and, subsequently, to Vice President, Oncology Clinical Development, Global Head Prostate Cancer Portfolio. In these roles, she effectively led the team to build a broad development strategy, which was flawlessly executed, resulting in acceleration of key development milestones and delivery of high-quality data to inform decision making. She successfully built and managed several drug development programs during the past five years and has led the team to the first regulatory submission and U.S. Food and Drug Administration approval of a treatment for patients with non-metastatic castration-resistant prostate cancer.
Prior to Janssen, Margaret was Director of Clinical Research at Myriad Pharmaceuticals, Inc. (Myrexis, Inc.), where she provided clinical leadership and medical monitoring oversight for all clinical trials in oncology. She led the development of treatments for two solid tumor malignancies. Before joining the pharmaceutical industry, she worked as Assistant Professor, Hematology Division, Internal Medicine Department at the University of Utah.
Margaret completed her residency in Internal Medicine and fellowship in Medical Oncology and Hematology at the University of Utah School of Medicine. She is board-certified in Internal Medicine and Medical Oncology and has authored numerous publications.